β-Lapachone Induces Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells

[1]  A. Pardee,et al.  Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Pardee,et al.  Release of Mitochondrial Cytochrome C in Both Apoptosis and Necrosis Induced by β-Lapachone in Human Carcinoma Cells , 1999, Molecular medicine.

[3]  R. Agarwal,et al.  Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Cundari,et al.  DNA damage and cytotoxicity induced by beta-lapachone: relation to poly(ADP-ribose) polymerase inhibition. , 1998, Mutation research.

[5]  D. Boothman,et al.  Induction of apoptosis in MCF-7: WS8 breast cancer cells by β-Lapachone , 1998 .

[6]  F. Sinicrope,et al.  Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Y. Pommier.  Diversity of DNA topoisomerases I and inhibitors. , 1998, Biochimie.

[8]  Y. Chau,et al.  beta-Lapachone induced cell death in human hepatoma (HepA2) cells. , 1998, Histology and histopathology.

[9]  P. Seth,et al.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. , 1997, Cancer research.

[10]  J. Dichgans,et al.  Topoisomerase‐I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl‐2 expression and of CD95‐mediated apoptosis by camptothecin and β‐lapachone , 1997, International journal of cancer.

[11]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[12]  A. Fornace,et al.  Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells , 1997, Oncogene.

[13]  A. Liu,et al.  Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. , 1997, Cancer research.

[14]  L. Strong,et al.  Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. , 1996, Oncogene.

[15]  K. Vousden,et al.  p53 in signaling checkpoint arrest or apoptosis. , 1996, Current opinion in genetics & development.

[16]  Y. Pommier,et al.  Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. , 1996, Oncology research.

[17]  S. Lowe,et al.  Cancer therapy and p53. , 1995, Current opinion in oncology.

[18]  D. Green,et al.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl , 1995, The Journal of experimental medicine.

[19]  E. Nabel,et al.  The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo , 1995, Nature Medicine.

[20]  A. Pardee,et al.  Induction of Apoptosis by β-Lapachone in Human Prostate Cancer Cells , 1995 .

[21]  G. Wilding,et al.  Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. , 1995, Cancer research.

[22]  S. Korsmeyer.  Regulators of cell death. , 1995, Trends in genetics : TIG.

[23]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[24]  P. Guiraud,et al.  Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. , 1994, Planta medica.

[25]  M. Pagano,et al.  Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. , 1994, Genes & development.

[26]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[27]  A. Pardee,et al.  beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. , 1993, The Journal of biological chemistry.

[28]  L. Berghella,et al.  The production of chromosomal alterations by beta-lapachone, an activator of topoisomerase I. , 1993, Mutation research.

[29]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[30]  C. Crumpacker,et al.  Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Kathleen R. Cho,et al.  Suppressor gene alterations in the colorectal adenoma‐carcinoma sequence , 1992, Journal of cellular biochemistry. Supplement.

[32]  D. Boothman,et al.  Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. , 1989, Cancer research.

[33]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[34]  S. Greer,et al.  Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran- 5,6-dione), a novel DNA repair inhibitor. , 1987, Cancer research.

[35]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[36]  A. Pardee,et al.  β-Lapachone greatly enhances MMS lethality to human fibroblasts , 1984 .

[37]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[38]  R. Docampo,et al.  In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi. , 1978, Annals of tropical medicine and parasitology.

[39]  R. Docampo,et al.  Generation of Superoxide Anions and Hydrogen Peroxide from β-Lapachone in Bacteria , 1978, Antimicrobial Agents and Chemotherapy.

[40]  W. Wehrli,et al.  β‐Lapachone, an Inhibitor of Oncornavirus Reverse Transcriptase and Eukaryotic DNA Polymerase‐α , 1978 .

[41]  W. de Souza,et al.  Effect of beta-lapachone on hydrogen peroxide production in Trypanosoma cruzi. , 1978, Acta tropica.